Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: CYBERKEN who wrote (10609)	11/1/1997 12:48:00 AM
From: Andrew H	Respond to of 32384

Cyberken, no longer IBD; we have been downgraded to BW Online. I only hope its in the magazine also.

To: CYBERKEN who wrote (10609)	11/1/1997 8:36:00 AM
From: Henry Niman	Respond to of 32384

CYBERKEN, I think that the trader just showed up late (when LGND was heading north on light volume) and just brought the price down very quickly because of the tight time frame. There was a fair amount of buying below $15, but it took awhile since it was all retail. As far as the LGND articles are concerned, I think it has to do somewhat on how positive the article is, and where it appears. IBD did a nice article on ALRI a week or two after the International Panretin trial halt, but it did little for LGND's stock price. However, it's now November and Biotechs typicalling rally at the end of the year. LGND has quite a few promising clinicals under its belt, and several new drugs ready to enter the market as well as sound financials, so that may just what buyers want, and a little publicity may go a long way (and LGND should get quite a bit of publicity).